Placebo News and Research

RSS

Taking probiotics during pregnancy has no effect on asthma rate amoung infants

Taking probiotics has health benefits but preventing childhood asthma isn't one of them, shows newly published research led by medical scientists at the University of Alberta.

9 Dec 2013

Janssen reports positive pivotal Phase 2 study data of siltuximab for Multicentric Castleman's Disease

Janssen Research & Development, LLC today announced positive results from a pivotal Phase 2 global registration study (MCD2001) suggesting siltuximab, an investigational compound, along with best supportive care, exhibited statistically significant efficacy and a tolerable safety profile compared with placebo and BSC in treating patients with the rare disorder Multicentric Castleman's Disease who are HIV-negative and human herpes virus 8-negative.

8 Dec 2013

Auxilium Pharmaceuticals' XIAFLEX gets FDA approval for treatment of Peyronie's disease

Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, announced today that the U.S. Food and Drug Administration has approved XIAFLEX (collagenase clostridium histolyticum, or CCH), an in-office, biologic for the treatment of Peyronie's disease. XIAFLEX is the first and only FDA-approved treatment proven effective for PD in men with a palpable plaque and a curvature deformity of 30 degrees or greater at the start of therapy.

6 Dec 2013

Women with moderate to severe menstrual cramps may find relief in erectile dysfunction drugs

Women with moderate to severe menstrual cramps may find relief in a class of erectile dysfunction drugs, according to a team of researchers led by Penn State College of Medicines Richard Legro.

6 Dec 2013

Eli Lilly reports edivoxetine Phase III program did not meet primary endpoint for major depressive disorder

Eli Lilly and Company (NYSE: LLY) announced today that results from three studies of edivoxetine did not meet the primary study objective of superior efficacy in depression after eight weeks of treatment.

6 Dec 2013

Eisai reports new data analyses on FYCOMPA (Perampanel) at AES meeting

Today, Eisai Inc. announced that 16 abstracts highlighting new data analyses on FYCOMPA (perampanel) will be presented at the 67th annual American Epilepsy Society (AES) meeting, taking place in Washington, D.C. from December 6 – 10.

6 Dec 2013

Genocea commences GEN-004 Phase 1 study to prevent pneumococcus infections

Genocea Biosciences, Inc., a clinical-stage company pioneering novel T cell vaccines, announced today that it has initiated a Phase 1 study of GEN-004, an investigational vaccine candidate for pneumococcus (Streptococcus pneumoniae), a major cause of infectious disease-related death globally. GEN-004 is the first vaccine candidate designed to prevent infections caused by all strains of pneumococcus through a novel T cell-mediated mechanism of action.

5 Dec 2013

AtheroNova completes active treatment portion of Phase 1 clinical trial with AHRO-001

AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the completion of the active treatment portion of its Phase 1 clinical trial with its lead compound, AHRO-001. The Phase 1 study objective is to evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers. The clinical study is being conducted in Russia with AtheroNova's licensing partner, OOO CardioNova.

5 Dec 2013

Soligenix initiates SGX942 Phase 2 study for treatment of oral mucositis

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has initiated a Phase 2, randomized, double-blind, placebo-controlled study evaluating SGX942, a first-in-class innate defense regulator, as a treatment for oral mucositis in patients undergoing chemoradiation therapy for head and neck cancer.

5 Dec 2013

New studies offer hope to women who want to get sexual mojo back

For women, passing midlife can deal a blow to their sex drive. But two new studies just published online in Menopause, the journal of The North American Menopause Society, offer hope to women who want to get their sexual mojo back.

5 Dec 2013

TB vaccine may help prevent multiple sclerosis

A vaccine used to prevent tuberculosis in other parts of the world may help prevent multiple sclerosis in people who show the beginning signs of the disease, according to a new study published in the December 4, 2013, online issue of Neurology, the medical journal of the American Academy of Neurology.

5 Dec 2013

Research: Omega-3 fatty acids in dietary supplements can cross blood brain barrier in Alzheimer's patients

New research from Karolinska Institutet in Sweden shows that omega-3 fatty acids in dietary supplements can cross the blood brain barrier in people with Alzheimer's disease, affecting known markers for both the disease itself and inflammation.

4 Dec 2013

Presence of ERG protein in biopsied prostate tissue increases likelihood of cancer development

Researchers from Weill Cornell Medical College have shown that the presence of a particular protein in biopsied prostate tissue substantially increases the likelihood that cancer will develop in that organ. The discovery will likely help physicians decide how closely to monitor men potentially at risk for the cancer -- among the most confusing and controversial dilemmas in health care.

4 Dec 2013

Lexicon announces top-line results from initial Phase 2 study of LX1033 for treatment of IBS-d

Lexicon Pharmaceuticals, Inc. today announced top-line results from an initial Phase 2 study exploring the use of LX1033 in diarrhea-predominant irritable bowel syndrome. LX1033 is an investigational drug that inhibits serotonin synthesis in the gastrointestinal tract. Serotonin is a neurotransmitter that has been shown to play a role in the symptoms of irritable bowel syndrome.

3 Dec 2013

Forest Laboratories to acquire exclusive rights in the U.S. for Saphris sublingual tablets

Forest Laboratories Holdings Limited, a wholly owned subsidiary of Forest Laboratories, Inc. today announced that the company is acquiring exclusive rights in the United States for Saphris (asenapine) sublingual tablets, a treatment for adult patients with schizophrenia or acute bipolar mania, from Merck Sharp & Dohme B.V., a wholly owned subsidiary of Merck & Co., Inc.

3 Dec 2013

Soligenix initiates orBec Phase 2 study for GI manifestations of chronic GVHD

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has initiated a Phase 2, randomized, double-blind, placebo-controlled study evaluating orBec (oral beclomethasone 17,21-dipropionate or BDP) as a treatment for the gastrointestinal manifestations of chronic Graft-versus-Host disease.

2 Dec 2013

InnaVirVax starts VAC-3S Phase 2 clinical trial for treatment of HIV-1 infection

InnaVirVax SA today announced the initiation of a Phase 2 clinical trial assessing the therapeutic properties of the VAC-3S vaccine when combined with standard antiretroviral therapy in the course of HIV-1 infection.

1 Dec 2013

Modafinil in combination with antidepressants reduces severity of depression more effectively

A new study has concluded that taking the drug modafinil, typically used to treat sleep disorders, in combination with antidepressants reduces the severity of depression more effectively than taking antidepressants alone.

28 Nov 2013

Researchers show benefits from testosterone administration in hysterectomized women

Hysterectomy and oophorectomy (the removal of ovaries) are performed to treat various diseases in women, including cancer. These procedures are accompanied not only by a decline in estrogen but also testosterone levels in the blood.

27 Nov 2013

Probiotic drink changes reaction of cells lining nasal passages of hay fever sufferers

A study has shown that a daily probiotic drink changed how cells lining the nasal passages of hay fever sufferers reacted to a single out-of-season challenge. However, it did not lead to significant changes in hay fever symptoms, although this challenge test may not have accurately represented natural allergen exposure.

27 Nov 2013

Placebo News and Research

Taking probiotics during pregnancy has no effect on asthma rate amoung infants

Janssen reports positive pivotal Phase 2 study data of siltuximab for Multicentric Castleman's Disease

Auxilium Pharmaceuticals' XIAFLEX gets FDA approval for treatment of Peyronie's disease

Women with moderate to severe menstrual cramps may find relief in erectile dysfunction drugs

Eli Lilly reports edivoxetine Phase III program did not meet primary endpoint for major depressive disorder

Eisai reports new data analyses on FYCOMPA (Perampanel) at AES meeting

Genocea commences GEN-004 Phase 1 study to prevent pneumococcus infections

AtheroNova completes active treatment portion of Phase 1 clinical trial with AHRO-001

Soligenix initiates SGX942 Phase 2 study for treatment of oral mucositis

New studies offer hope to women who want to get sexual mojo back

TB vaccine may help prevent multiple sclerosis

Research: Omega-3 fatty acids in dietary supplements can cross blood brain barrier in Alzheimer's patients

Presence of ERG protein in biopsied prostate tissue increases likelihood of cancer development

Lexicon announces top-line results from initial Phase 2 study of LX1033 for treatment of IBS-d

Forest Laboratories to acquire exclusive rights in the U.S. for Saphris sublingual tablets

Soligenix initiates orBec Phase 2 study for GI manifestations of chronic GVHD

InnaVirVax starts VAC-3S Phase 2 clinical trial for treatment of HIV-1 infection

Modafinil in combination with antidepressants reduces severity of depression more effectively

Researchers show benefits from testosterone administration in hysterectomized women

Probiotic drink changes reaction of cells lining nasal passages of hay fever sufferers

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News